ANI launches benztropine mesylate tablets

BAUDETTE, Minn. — ANI Pharmaceuticals has launched its benztropine mesylate tablets, the company announced Tuesday. The drug is the tenth commercial introduction the company has seen in 2016, according to CEO Arthur Przybyl. 

 

ANI’s benztropine mesylate tablets will be available in 0.5-, 1-, and 2-mg dosage strengths. The product has a current market size of about $25 million, according to IMS Health data.